Status:
UNKNOWN
Effects of Remifentanil on Cardiac Function in Patients With Diastolic Dysfunction
Lead Sponsor:
Yeditepe University
Conditions:
Diastolic Dysfunction
Eligibility:
All Genders
60-80 years
Phase:
PHASE4
Brief Summary
In this study ASA 1, 2 individuals with grade 1 or 2 diastolic dysfunction will be recruited to assess the effects of Remifentanil infusion on left ventricular function evaluated with transthoracic ec...
Detailed Description
Our aim in this study is to evaluate the effects of Remifentanil infusion on left ventricular function evaluated with transthoracic echocardiagraphy on ASA 1, 2 individuals with grade 1 or 2 diastolic...
Eligibility Criteria
Inclusion
- 60 years of age or older ASA 1, 2 adults with first or second degree diastolic dysfunction.
Exclusion
- Atrial fibrillation, Atrioventricular block, tachyarrhythmia, bradyarrhythmia, Left ventricular ejection fraction lower than 50%, body mass index \>30 kg/m2, Liver, kidney and lung disease.
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04117009
Start Date
November 1 2019
End Date
June 1 2020
Last Update
May 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yeditepe University Hospital
Istanbul, Ataşehir, Turkey (Türkiye), 34752